Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests

Who is this study for? Adult patients with dry eye disease
What treatments are being studied? Preservative-free Refresh Optive Advanced Lubricant Eye Drops
Status: Terminated
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This is a single site, prospective, cross-sectional, controlled clinical study on a total of 66 subjects. The subjects are divided into two groups: Hypertonic Saline Non-Responders (33 subjects) and Hypertonic Saline Responders (33 subjects). After completion of questionnaires, the subjects will undergo Dry Eye Disease testing and functional nerve testing. Subjects who qualify will be dispensed 4 weeks of preservative free artificial tears and instructed to instill one drop into each eye twice daily. Subjects will return for a follow up visit 4 weeks later (± 4 days), during which subjects will complete the questionnaires again and the Dry Eye Disease tests and functional nerve tests will be repeated.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

∙ Group 1 (Hypertonic saline non-responders):

• At least 18 years of age

• Ability to consent

• Diagnosis of Dry Eye Disease (DED) based on:

‣ Symptoms of DED, shown with SANDE score of 50mm or greater

⁃ Two or more of the following objective signs in the same eye: 1. Schirmer test of 10 mm or less over 5 minutes; 2. Fluorescein tear break-up time (FTBUT) of 7 seconds or less; 3. Meibomian gland expression (MGE) grade of 2 or greater for at least 3 out of 5 glands

• HS response result of one of the following:

‣ Reduction of discomfort/pain rating

⁃ No change of discomfort/pain rating

⁃ Increase in discomfort/pain rating score of 1 step or less

∙ Group 2 (Hypertonic saline non-responders):

• At least 18 years of age

• Ability to consent

• Diagnosis of DED based on:

‣ Symptoms of DED, shown with SANDE score 50mm or greater

⁃ Two or more of the following objective signs in the same eye: 1. Schirmer test of 10 mm or less over 5 minutes; 2. Fluorescein tear break-up time (FTBUT) of 7 seconds or less; 3. Meibomian gland expression (MGE) grade of 2 or greater for at least 3 out of 5 glands

• HS response result of an increase in discomfort/pain rating of greater than 1 step

Locations
United States
Massachusetts
Tufts Medical Center-New England Eye Center
Boston
Time Frame
Start Date: 2019-10-03
Completion Date: 2025-07-31
Participants
Target number of participants: 36
Treatments
Experimental: Hypertonic Saline Responders
Subjects who qualify as hypertonic saline responders will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
Experimental: Hypertonic Saline Non-responders
Subjects who qualify as hypertonic saline non-responders will be dispensed the same instructions and treatment as the Hypertonic Saline Responders. They will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
Authors
Stephanie Cox
Related Therapeutic Areas
Sponsors
Leads: Tufts Medical Center

This content was sourced from clinicaltrials.gov